AngioDynamics Earnings Reports

AngioDynamics delivered an outstanding first quarter for fiscal year 2026, with net sales increasing by 12.2% to $75.7 million. The Med Tech segment continued its strong momentum with 26.1% revenue growth, marking its fourth consecutive quarter of over 20% growth. The company also reported positive Adjusted EBITDA of $2.2 million, a significant improvement from a loss in the prior year, and ended the quarter with $38.8 million in cash and cash equivalents, ahead of expectations.

The company achieved 12.7% revenue growth in Q4 2025, driven by 22% Med Tech sales increase. It recorded a GAAP net loss but improved adjusted EBITDA, supported by operational efficiency and strong cash flow.

AngioDynamics posted $72M in revenue and narrowed its adjusted net loss, driven by double-digit Med Tech sales growth and improved gross margins. The company reported positive adjusted EBITDA and raised full-year guidance.

AngioDynamics reported a 9.2% increase in net sales to $73.0 million, driven by a 25% increase in Med Tech sales. The company achieved adjusted EBITDA of $3.1 million and a GAAP loss per share of $(0.26). They also received CPT Category I Codes for IRE and FDA 510(k) clearance for NanoKnife Prostate Tissue Ablation.

AngioDynamics reported a 1.1% increase in net sales compared to the prior-year quarter, with Med Tech net sales up by 8.7%. The company's GAAP loss per share was $0.31, and the adjusted loss per share was $0.11. The company submitted for FDA 510(k) clearance for Prostate Tissue indication for NanoKnife, received CE Mark Approval in Europe for the Auryon System, and initiated RECOVER-AV Clinical Trial in Europe for AlphaVac.

AngioDynamics reported Q4 2024 net sales of $71.1 million, a 1.9% increase year-over-year. The company's Med Tech business saw an 11.3% increase, while the Med Device business decreased by 3.8%. The company achieved FDA 510(k) clearance and CE Mark approval for AlphaVac F18 System for the treatment of Pulmonary Embolism (PE).

AngioDynamics reported an 8.0% increase in net sales to $66.0 million for the third quarter of fiscal year 2024, driven by growth in both Med Tech and Med Device portfolios. The company completed the sale of its PICC and Midline product portfolios and reached a settlement agreement with BD/Bard. They also received FDA 510(k) clearance for AlphaVac in the treatment of pulmonary embolism.

AngioDynamics reported a 2.7% increase in net sales to $79.1 million for Q2 2024 on a pro forma basis. The company is undergoing a strategic transformation, including restructuring its manufacturing and optimizing its portfolio, expecting adjusted EPS profitability in FY27.

AngioDynamics reported net sales of $78.7 million. GAAP earnings per share was $1.15, while adjusted loss per share was $0.12. The company reaffirmed its fiscal year 2024 guidance.

AngioDynamics reported a 4.7% increase in net sales for the fourth quarter of fiscal year 2023, driven by growth in its Med Tech segment. The company's GAAP loss per share was $0.54, which included a goodwill impairment of $14.5 million. Adjusted earnings per share were $0.02. The company completed the sale of its Dialysis and BioSentry Biopsy businesses and provided FY24 guidance.

AngioDynamics reported a 9.1% increase in net sales to $80.7 million, driven by growth in Med Tech and Med Device segments. The company experienced a decrease in gross margin to 50.2% due to inflationary pressures, and a net loss of $9.5 million, or $0.24 per share.

AngioDynamics reported a 9.1% increase in net sales to $85.4 million for Q2 2023, with Med Tech sales up 29.7% and Med Device sales up 2.6%. The company's gross margin increased by 100 basis points to 52.8%. GAAP loss per share was $0.21, while adjusted earnings per share was $0.01.

AngioDynamics reported a 5.9% increase in net sales compared to the prior-year quarter. Med Tech net sales increased 29.6%, while Med Device net sales decreased 1.1%. The company's GAAP loss per share was $0.33, and adjusted loss per share was $0.06.

AngioDynamics reported a strong fourth quarter in fiscal year 2022, with net sales reaching $87.0 million, a 13.2% increase compared to the prior-year quarter. The growth was primarily driven by the Med Tech portfolio, which saw a 40.0% increase in net sales. The company reported a GAAP loss per share of $0.16 and an adjusted earnings per share of $0.01. AngioDynamics issued fiscal year 2023 guidance, expecting net sales to be in the range of $342 to $348 million and adjusted earnings per share in the range of $0.01 to $0.06.

AngioDynamics reported a 3.9% increase in net sales for the third quarter of fiscal year 2022, reaching $74.0 million. Med Tech sales grew by 28.6%, while Med Device sales declined by 2.8%. The company experienced a net loss of $5.0 million, or $0.13 per share, but adjusted earnings per share were $0.03. Gross margin was 52.2%, impacted by supply chain disruptions, procedural challenges, and inflation. The company reaffirmed its fiscal year 2022 guidance.

AngioDynamics reported a 7.6% increase in net sales to $78.3 million for the second quarter of fiscal year 2022. Revenue growth was driven by the Med Tech segment, which increased 36.4% year-over-year. However, the company experienced a decline in gross margin and a net loss due to supply chain constraints, labor shortages, and lower procedural volumes.

AngioDynamics reported a 9.6% increase in net sales compared to the prior-year quarter, driven by Med Tech growth. However, the company reported a net loss of $7.0 million, or $0.18 per share, and an adjusted loss per share of $0.02. The gross margin increased by 120 basis points year over year.

AngioDynamics reported a strong Q4 2021 with a 31.7% increase in net sales compared to the prior-year quarter. The company's gross margin improved by 330 basis points year over year. The company is now trending close to normalized run rates. The company recorded a net loss of $19.5 million, or a loss per share of $0.51.

AngioDynamics reported a 2.0% increase in net sales compared to the prior-year quarter. The company's revenue grew despite COVID-19 headwinds. The company is raising its fiscal year 2021 guidance.

AngioDynamics reported a 4.0% increase in net sales to $72.8 million compared to the prior-year quarter. The company's gross margin declined to 55.2%, and GAAP loss per share was $0.11, while adjusted earnings per share was $0.01. They reaffirmed their fiscal year 2021 net sales guidance between $278 and $284 million and adjusted earnings per share between $0.00 and $0.05.

AngioDynamics reported a strong first quarter with net sales of $70.2 million, a 6.3% increase compared to the prior-year quarter. The company's gross margin was 50.9%, and they reported a GAAP loss per share of $0.11 and adjusted earnings per share of $0.02. They expect fiscal year 2021 net sales between $278 and $284 million and fiscal year 2021 adjusted earnings per share between $0.00 and $0.05.

AngioDynamics reported a decrease in net sales by 18.1% compared to the prior-year quarter, with net sales of $58.3 million. The company's performance was impacted by the deferral of elective procedures associated with COVID-19. Gross margin declined to 51.8%, and the company reported a GAAP loss per share of $4.10, which includes a goodwill impairment. Adjusted loss per share was $0.06. The company is focused on managing through the impacts of COVID-19 and remains focused on its long-term strategy.

AngioDynamics reported a 6.5% increase in net sales for the third quarter of fiscal year 2020, reaching $69.8 million. The company's gross margin was 57.8%, a slight decrease of 40 basis points year over year. The company experienced a net loss from continuing operations of $5.7 million, or a loss of $0.15 per share, while adjusted earnings per share were $0.01. Due to the uncertainty created by the COVID-19 pandemic, management is withdrawing its fiscal year 2020 financial guidance.

AngioDynamics reported flat net sales of $70.0 million compared to the prior-year quarter. Gross margin increased by 140 basis points to 59.3%. The company announced the acquisition of the C3 Wave PICC tip location system. They reiterate FY2020 guidance expecting net sales between $280 to $286 million and adjusted EPS between $0.10 to $0.15.